Relief Therapeutics

Relief Therapeutics is a biopharmaceutical company focused on serious diseases with unmet medical needs. By rapidly developing late-stage clinical assets, Relief Therapeutics aims to bring treatment options to patients as soon as possible. Relief Therapeutics is currently concentrating on three therapeutic areas: Rare Metabolic Disorders, Rare Skin Diseases, and Rare Respiratory Diseases. The company’s leading candidate product is RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with a multi-faceted mode of action for respiratory indications. The current focus of the development program is on severe lung injury and pulmonary sarcoidosis caused by Covid-1. Clinical development opportunities for RLF-100™ in other acute and chronic lung disease indications are currently being evaluated.